Skip to main content
PLOS One logoLink to PLOS One
. 2021 Apr 29;16(4):e0251013. doi: 10.1371/journal.pone.0251013

Increased expression of Netrin-4 is associated with allodynia in a trigeminal neuropathic pain model rats by infraorbital nerve injury

Yuka Honjo 1,2, Yuki Fujita 1,3, Hitoshi Niwa 2, Toshihide Yamashita 1,3,4,5,*
Editor: Masabumi Minami6
PMCID: PMC8084253  PMID: 33914819

Abstract

Neuropathic pain refers to pain caused by lesions or diseases of the somatosensory nervous system that is characteristically different from nociceptive pain. Moreover, neuropathic pain occurs in the maxillofacial region due to various factors and is treated using tricyclic antidepressants and nerve block therapy; however, some cases do not fully recover. Netrin is a secreted protein crucially involved in neural circuit formation during development, including cell migration, cell death, neurite formation, and synapse formation. Recent studies show Netrin-4 expressed in the dorsal horn of the spinal cord is associated with chronic pain. Here we found involvement of Netrin-4 in neuropathic pain in the maxillofacial region. Netrin-4, along with one of its receptors, Unc5B, are expressed in the caudal subnucleus of the trigeminal spinal tract nucleus. Inhibition of its binding by anti-Netrin-4 antibodies not only shows a behavioral analgesic effect but also neuronal activity suppression. There was increased Netrin-4 expression at 14 days after infraorbital nerve injury. Our findings suggest that Netrin-4 induced by peripheral nerve injury causes neuropathic pain via Unc5B.

Introduction

Neuropathic pain is defined as “pain caused by a lesion or disease of the somatosensory system” by the International Association for the Study of Pain [1] and is characteristically different from nociceptive pain. It involves spontaneous sensations (persistent or intermittent) and stimulation-induced pain (allodynia and hyperalgesia) in areas coinciding with the impaired innervation area, as well as various sensations induced by nerve damage. Moreover, there is a characteristic of converging abnormalities [2]. It might also involve the trigeminal nerve region as a result of various factors, including surgery-induced trauma, tumors, neurodegenerative diseases, etc. Specifically, during dental treatments, nerves are inevitably mechanically cut during teeth extraction; moreover, there could be accidental damage to the lingual nerve and inferior alveolar nerve during oral surgery. Consequently, there is a high possibility of neuropathic pain caused by nerve damage [3]. Its pharmacological treatments include tricyclic antidepressants, selective norepinephrine and serotonin reuptake inhibitors, opioid agonists, and nerve block treatments. However, there are some cases of insufficient analgesic effect or where treatment cannot be used due to age or side effects [4]. Therefore, there is a need to establish an effective treatment by elucidating a novel molecular mechanism.

Netrin, which is a laminin-related extracellular protein, was originally identified as an attractant molecule for axon guidance in the embryonic spinal cord [5, 6]. In mammals, there are four secreted types (Netrin-1, -3, -4, and -5) and two glycosylphosphatidylinositol-anchored types (Netrin-G1 and -G2) [68]. Secreted Netrins bind to DCC (deleted in colorectal cancer), Neogenin, and Unc5 (A-D) while Netrin-Gs bind to different proteins [9]. Previous studies have demonstrated the important roles of Netrin in cell migration, survival, axon branching, and synaptogenesis during neural development [1013]. The role of Netrin during adulthood has remained unclear; however, there have been recent reports regarding its role.

Netrin-4 is very homologous to the laminin β1 chain. In adults, Netrin-4 is expressed in the lung, kidney, blood vessel, and most brain parts, including the upper trigeminal spinal tract nucleus [14]. Further, Netrin-4 binds to Unc5B in the spinal cord [13, 15]. We previously reported that Netrin-4 delivered by dorsal horn interneurons was involved in inflammatory and neuropathic pain and that inhibition of Netrin-4 binding to Unc5B suppressed post-nerve-injury neuropathic pain [16].

This study aimed to investigate the role of Netrin-4 in orofacial neuropathic pain. Specifically, we aimed to examine Netrin-4 and Unc5B expression in the trigeminal subnucleus caudalis (Vc) of adult rats after infraorbital nerve injury, as well as Netrin-4 effects on mechanical sensitivity using anti-Netrin-4 antibody administration in a chronic pain model.

Materials and methods

Animals

6-9-wk-old male Sprague-Dawley rats (190–300 g; Japan SLC) were used in this study. All experiments were accordance with the Osaka University Medical School Guide for the Care and Use of Laboratory Animals and were approved by Institute Committee of Osaka University (Permit Number: 28–058).

Models for orofacial neuropathic pain

Chronic constriction injury to rat’s infraorbital nerve (CCI-ION) was performed with some changes as has been previously described [17]. Rats were put under isoflurane anesthesia. A small incision was made at the edge of the left whisker pad, and left ION was exposed. Two nylon sutures (6–0 thread) were placed 2mm apart around the ION, and the wound was sutured after ligation of the ION. These ligations reduced the diameter of the nerve, but did not occlude it completely (CCI: ipsilateral side). And contralateral ION was exposed but did not undergo nerve ligation for sham injury (Sham: contralateral side). Hereinafter it is described as ‘CCI-Sham injury’. We used this model for all subsequent experiments, and the total number of rats which were analyzed in this study were 86 (make animal models; n = 23, administration of antibody; n = 27, immunohistochemical staining; n = 20, quantitative PCR; n = 16).

Behavioral testing

The mechanical sensitivity of animals was assessed by using the von Frey filament test, as previously described [18]. Rats were placed on an acrylic box (30×30×30 cm) and habituated for 5–10 min before any stimulation. Then mechanical stimulations (4,8,15 and 26 g) were applied to center of the whisker pad using von Fry filaments (Semmes-Weinstein Von Frey esthesiometer, Muromachi Kikai Co.). The head-withdrawal threshold of the mechanical stimulation on the whisker pad skin was defined as minimum pressure needs to evoke at least three reactions by five stimuli (positive reaction; withdrawal of the head, or an attack or escape). The cutoff to prevent tissue damage was determined as 26 g. Before CCI-sham injury, stimulation with 26 g filament did not induce any nociceptive reaction. The stimuli were applied before injury and 7, 14, 21 days after injury.

Intracisternal administration of drugs

At 14 days after CCI-Sham injury, rats were tested their behavior before administration and put under isoflurane anesthesia. Anesthesia rats were placed in a head holder. A skin incision was made from the back of calvarium to top of cervical spine. The atlanto-occipital membrane was dissected under a surgical microscope, and a micro syringe with a 29-gauge needle inserted into cisterna magna. A mouse anti-Netrin-4 antibody (AF1132, R&D Systems) or Normal Goat IgG (144–09531, Wako) was diluted to 30 μg with 50μl saline and infusions of drags were performed slowly. The skin and muscle wound were sutured rapidly.

Immunohistochemistry

Immunohistochemistry was performed as described previously (Hayano et al., 2016). 30 minutes after the behavior test, rats were deeply anesthetized and then transcardially perfused with 100ml PBS, followed by 200ml of ice-cold 4% paraformaldehyde (PFA) in a 0.1M phosphate buffer. Vc and upper cervical cord (C1-C2) were dissected and post-fixed in 4% PFA for 24 hours at 4°C. Tissues were transferred and stored in 30% sucrose in PBS 48 hours at 4°C. 30μm coronal sections were cut on a cryostat. Sections washed three times and incubated in blocking solution (5% BSA and 0.3% Triton X-100 in PBS) for 1 hour at room temperature. For double-labelling immunofluorescence histochemistry, sections were incubated for 24 or 48 h at 4°C with antibodies against Netrin-4 (1:50; HPA049832; ATLAS), Unc5B (1:200; HPA01141, ATLAS), NeuN (1:1000; MAB377, Millipore), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (1:200; #4370, CST), Iba1(1:200; ab5076, abcam), GFAP (1:200; G-A-5, Sigma-Aldrich). The sections were washed 3 times and incubated for 2 h at room temperature or overnight at 4°C with secondary antibodies (Alexa Fluor 488/568/594; 1:500; Thermo Fisher Scientific, Inc.). The sections were washed 3 times, slide-mounted, and cover-slipped in mounting medium with the nuclear stain 4ʹ,6-diamidino-2-phenylindole (DAPI, Vector Laboratories).

The number of pERK positive neurons in the all area of Vc and the laminae II of C1 was counted. The mean number of pERK-immunoreactive (pERK-IR) neurons was calculated from 6 tissue sections (Positions: -2160, -1440, -720, 0, +720 and +1440 μm from the obex).

Quantitative PCR

Total RNA was extracted from the Vc-C1 which was collected by Laser Microdissection technique (LMD7000, Leica) with TRIzol reagent (15596018, Invitrogen). After cDNA synthesis (High Capacity cDNA RT Kit, Applied Biosystems), gene expression was quantified with a TaqMan Gene Expression Assay (Applied Biosystems). The following Taqman Assays were used: Netrin-4 (Rn01760394_m1); Unc5B (Rn00573551_m1). Cycle threshold (Ct) values were calculated using the ΔΔCt method. All ΔCt values were normalized to rat glyceraldehyde-3-phosphate dehydrogenase (Rn99999916_s1)

Experimental design and statistical analysis

Statistical analysis was performed using the Mann-Whitney test for comparisons between two groups. For comparisons among multiple groups, the two-way Repeated-Measure ANOVA with the Bonferroni post-hoc test and 3-way ANOVA with the Tukey post-hoc tests or the Dunnett post-hoc tests were used. Differences with P <0.05 were considered statistically significant. Statistical analyses were performed using Prism software (GraphPad software In.). All data are presented as the mean ± standard error of the mean.

Results

Development of hyperalgesia after CCI-Sham injury

The CCI-ION rat has been studied as a model of orofacial neuropathic pain [17, 19, 20]. To assess the pain-related behavior of the orofacial neuropathic pain rat model, we measured their head-withdrawal threshold to the whisker pad skin using the von Frey filament test. There was a significant decrease in the head-withdrawal threshold for mechanical stimulation of the ipsilateral side at 14 and 21 days after injury compared with the pre-injury day (Fig 1). There was no significant change in the contralateral side on any day.

Fig 1. Time course of the development of hyperalgesia after chronic constriction injury (CCI) of infraorbital nerve (ION).

Fig 1

Head-withdrawal thresholds after CCI-Sham injury. The ipsilateral side shows significantly decrease compared to contralateral side at 14 and 21 day after injury (n = 7). The data are presented as the mean ± SEM.*, P<0.05; Bonferroni test (contra; contralateral, ipsi; ipsilateral).

Netrin-4 antibody attenuates pain-related behavior in a trigeminal neuropathic pain rat model

We directly administered anti-Netrin-4 antibody to the cisterna magna to examine whether anti-Netrin-4 antibody, which has an analgesic effect on neuropathic pain caused by sciatic nerve injury [16], exerted an analgesic effect on neuropathic pain caused by infraorbital nerve injury.

First, Evans Blue was administered to confirm whether the antibody added from the cisterna magna reached the target Vc-C1 region (Fig 2A). Second, a fluorescent-labeled anti-Netrin-4 antibody was administered from the cisterna magna and analyzed to confirm whether it would bind to neuronal cells in the Vc (Lightning-Link Rapid Conjugation System DyLight488, Innova Biosciences), which was confirmed (Fig 2B and 2C).

Fig 2. Effects of anti-Netrin-4 antibody administration on pain behavior in trigeminal neuropathic pain model rats.

Fig 2

(A) Confirmation of administration area by Evans Blue. (B and C) Penetration of anti-Netrin-4 antibody (Antibody) into the Vc. Double immunofluorescence staining for the fluorescence dye-conjugated Netrin-4 antibody (DyLight 488; green) and NeuN (red). The fluorescence of antibody was observed on neurons (arrowhead) in Vc. (C) is high magnification image corresponding to the square area in (B). Bars: (B) 100 μm, (C) 20 μm. (D) Head-withdrawal threshold after administration control IgG or anti-Netrin-4 antibody to CCI-ION or Sham injury (n = 5). The data are presented as the mean ± SEM. *, P<0.05; Tukey test.

After confirming that the antibody reached the target region after administration through direct puncture of the cisterna magna, we assessed changes in the head-withdrawal threshold after antibody administration. The anti-Netrin-4 or Control antibodies were administrated at 14 days after CCI-Sham injury. Compared with the Control antibody group, the anti-Netrin-4 antibody group showed a significant increase in the head-withdrawal threshold of the ipsilateral side after one day of administration (at 15 days after CCI-Sham injury) (Fig 2D).

Suppression of the neuronal activation by anti-Netrin-4 antibody in the Vc

A previous study [16] reported that neurons were activated by Netrin-4 administration to the spinal cord. Therefore, we performed immunohistochemistry to determine the effect of anti-Netrin-4 antibody on neuronal activation in the Vc.

After the 14 treatment days where the head-withdrawal threshold was significantly altered by the CCI-Sham injury, there was the expression of anti-pERK antibody-positive cells on both the ipsilateral and contralateral sides (Fig 3A and 3B). There was a significant increase in the number of cells positive for both the anti-pERK and anti-NeuN antibodies on the ipsilateral side. However, we could not observe the pERK signals in Iba-1-positive cells (Fig 3C) or GFAP-positive cells (Fig 3D). Further, upon anti-Netrin-4 antibody administration, there was a significant decrease in the number of pERK-positive neurons on the ipsilateral side compared with the pre-administration values and those in the control antibody administration group (Fig 3E and 3F).

Fig 3. Suppression of neuronal activation by administration of anti-Netrin-4 antibody.

Fig 3

(A) pERK immunofluorescence (green) staining in the Vc of ipsilateral and contralateral side. (B) pERK and NeuN (red) double immunofluorescence staining. The arrowhead indicates pERK positive neurons. (C and D) pERK (green) and Iba1or GFAP (red) double immunofluorescence staining. Bar: (A) 100 μm, (B, C, D) 20 μm. (E) The mean number of pERK-positive neurons in Vc-C1 after control or anti-Netrin-4 antibody administration (n = 4–6). The data are presented as the mean ± SEM. *, P<0.05; Tukey-Kramer test. (F) pERK immunofluorescence (green) staining in the Vc of ipsilateral and contralateral side. There were a number of pERK-positive sells in ipsilateral side after control antibody treatment, whereas anti-Netrin-4 antibody treatment reduced the number of them. Bar: 100 μm.

Post-CCI increased Netrin-4 expression in the Vc

Previous studies have reported Netrin-4 and Unc5B expression in a healthy adult human brain; specifically, Netrin-4 expression in the trigeminal spinal subnucleus interpolaris (Vi) [14]. Consequently, we hypothesized that there was Netin-4 and Unc5B expression in the Vc. Immunohistochemical examination revealed anti-Netrin-4 and anti-Unc5B antibody-positive cells in the Vc. (Fig 4A–4F). Moreover, there was neuronal expression of Netrin-4 and Unc5B in the Vc (Fig 4D and 4F). Furthermore, to examine whether there was an association of changes in the head-withdrawal threshold with those in Netrin-4 and Unc5B expression in the Vc, we performed quantitative mRNA analysis by real-time PCR. Compared with pre-injury levels, there was a significant increase in the Netrin-4, but not Unc5b, levels from 7 to 21 days on both sides in the Vc after CCI (Fig 4G and 4H). We examined expression of Netrin-4 and Unc5B at 0 and 14 days (Fig 5A, 5B, 5E and 5F), and after anti-Netrin-4 antibody or control antibody treatment (Fig 5C, 5D, 5G and 5H). We did not observe the difference of the expression of Netrin-4 between ipsilateral and contralateral side in each group examined (Fig 5A–5H).

Fig 4. Netrin-4 and Unc5B receptors are expressed in Vc-C1.

Fig 4

(A and B) Immunofluorescence staining for Netrin-4 (A) and Unc5B (B) in Vc of the ipsilateral side and contralateral side. Bar:100μm. (C and D) Netrin-4 (green) and NeuN (red) double immunofluorescence staining in Vc of the ipsilateral side. Bar: (C) 100μm (D) 10μm. (E and F) Unc5B (green) and NeuN (red) double immunofluorescence staining in Vc of the ipsilateral side. Bar: (E) 100μm (F) 10μm. (G and H) Netrin-4 (G) and Unc5B (F) mRNA expression in the ipsilateral (ipsi) and contralateral (contra) side at 14days after CCI-Sham injury (n = 3–5). The right graphs show the other day time results. The data are presented as the mean ± SEM. *, P<0.05; Mann-Whitney test.

Fig 5. Expression of Netrin-4 and Unc5B receptor inVc-C1.

Fig 5

(A and B) Netrin-4 expression in Vc of ipsilateral and contralateral side at 0 and 14days. (C and D) Netrin-4 expression in Vc of ipsilateral and contralateral side after anti-Netrin-4 antibody or Control antibody treatment. (E and F) Unc5B expression in Vc of ipsilateral and contralateral side at 0 and 14days. (G and H) Unc5B expression in Vc of ipsilateral and contralateral side after anti-Netrin-4 antibody or Control antibody treatment. Bars: 100μm.

Discussion

The model of orofacial neuropathic pain established through infraorbital nerve injury

In this study, we used a rat model established through CCI-ION to analyze the effect of the anti-Netrin-4 antibody on trigeminal neuropathic pain. This model has been used in numerous studies [17, 19, 20]; moreover, it has been reported that chronic injury caused by peripheral nerve ligation induces allodynia or hyperalgesia to chemical, mechanical, and thermal stimuli [17, 21, 22]. In the established CCI-Sham injury model, infraorbital nerve ligation (CCI-injury) and non-ligation (Sham injury) were performed in the same rat. Numerous studies have analyzed the head-withdrawal threshold between the infraorbital nerve injury group (CCI-ION) and the pseudo injury group (Sham). A study reported a slightly decreased threshold on the injured and healthy side of the Sham and CCI-ION group, which recovered on 14 days after injury [19]. We observed recovery on the contralateral side and a significant decrease in the ipsilateral side at 14 days after injury. Therefore, to minimize the number of rats used in the experiment, we employed this method where the CCI-Sham injury was performed in the same rat.

The decreased escape thresholds caused by CCI-ION is observed from the first post-ligation day and lasts for at least 21 days [19, 20]. We observed the down threshold until 21 days after CCI-Sham injury. The hyperalgesia incidence on 14 days after CCI-Sham injury in our study was 30.4%, which is consistent with a previous study that employed a separate CCI and sham group [23].

Our findings indicated that allodynia developed on the ipsilateral side at 14 days after CCI-Sham injury and persisted until 21 days. Subsequent assessments of these rat models revealed a decreased head-withdrawal threshold at 14 days after injury.

The mechanism of hyperalgesia and the role of Netrin-4

Ligation and inflammation could induce peripheral nerve injury. Inflammatory factors, including bradykinin and prostaglandin, decrease the threshold of Transient Receptor Potential Vanilloid 1 and increase Na+ channel excitability via individual receptors located on the peripheral side of the primary afferent nerve, which causes peripheral sensitization [24]. Subsequently, glutamate, Substance P, and brain-derived neurotrophic factor released from the central site of the primary afferent nerve bind to individual neuron receptors in the secondary afferent nerve. This is followed by MEK phosphorylation, which leads to ERK activation. This leads to the activation of the cAMP response element-binding protein in the neuron nucleus and expression of various genes, including c-Fos and Neurokinin 1 (NK-1) [2527]. It has been reported that pERK triggers post-translational regulation of AMPA and NMDA receptor and contributes to central sensitization [2830]. This sensitization is thought to lead to increased neuronal excitability, as well as allodynia and hyperalgesia occurrence. After spinal cord injury, there is temporary pERK expression at the surface of the spinal dorsal horn; subsequently, there is long-term pERK expression in microglia and astrocytes [31]. Direct pERK inhibition by a selective MEK inhibitor reduces formalin-induced pain behavior. Therefore, pERK is considered to be deeply involved in neuropathic development and maintenance [32, 33]. We observed a greater increase in pERK-positive neurons in the ipsilateral side than in the contralateral side at 14 days after CCI-Sham injury. This suggests that peripheral and central sensitization occurred at 14 days after injury and that neurons of the Vc contribute to hyperalgesia through pERK expression. However, the number of pERK-positive neurons in our study was much less than that of previous reports [20, 34]. This could be partly attributed to differences in the mechanical stimulus intensity and stimulation method applied to the model. However, even with sciatic nerve or spinal cord injury induced by a slight stimulus, increased pERK expression has still been reported [35, 36]. Moreover, pERK expression has been reported to peak at several minutes after the noxious stimulus and to decrease by half after 10 minutes [32]. These findings suggest that differences in the number of cells could be attributed to differences in the time until tissue collection after mechanical stimulation. Further, there could have been reduced expression compared to that immediately after mechanical stimulation. Therefore, in the present study, if tissues had been collected sooner after mechanical stimulation, the number of pERK-positive neurons could have been confirmed to correspond to the observed pain behavior. Further, 30 minutes after mechanical stimulation, there was a small total number of pERK-positive neurons; nonetheless, it was significantly higher in the ipsilateral side than on the contralateral side. Moreover, sustained nerve cell activation may cause long-term neuropathic pain.

Contrastingly, upon spinal cord injury, SHP2 and NR2B, which are among the NMDA receptor subtypes, are activated when Netrin-4 secreted from interneurons in the lamina 2 of the dorsal horn binds to Unc5B [16]. Consequently, neurons are activated while neuropathic pain and inflammatory pain occurs. We observed that anti-Netrin-4 antibody administration through the cisterna magna increased the escape threshold by CCI-ION and reduced neuronal pERK expression in the Vc. However, Netrin-4 expression is increased also in the contralateral side at day 14. These findings suggest that Netrin-4 enhances hypersensitivity induced by damage to the infraorbital nerve, but that Netrin-4 is not sufficient to induce hypersensitivity. The molecular mechanism of the effect of Netrin-4 in the Vc might be explained by the previous observations that Netrin-4 binding to Unc5B leads to activation of SHP2 and the Ras-MAPK pathway [16, 3743].

The expression of Netrin-4 and Unc5B in Vc

Netrin-4 occurrence ranges widely in adult healthy brains in rats. It is not only expressed in the cerebral cortex but also the trigeminal spinal tract (Sp5) and Vi [14]. Therefore, Netrin-4 expression in the Vc is expected. Further, Unc5B has been reported as among the Netrin receptors that bind Netrin-1 or Netrin-4 [6, 13, 44].

Immunohistochemical analysis revealed Netrin-4 and Unc5B expression in the Vc~C1 at 14 days after CCI-Sham injury which was the day of hyperalgesia development. Moreover, quantitative mRNA analysis of the Vc~C1 indicated significantly increased Netrin-4 at 14 days after CCI-Sham injury compared with before injury. This indicates that hyperalgesia is caused by increased netrin-4 secretion, which triggers neuronal activation. In our study, although the number of Netrin-4-positive cells in the Vc appear to be a few, it may reflect the sensitivity of the antibodies employed. As Netrin-4 is a secreted protein, it would be difficult to detect the low amount of the Netrin-4 protein by immunohistochemistry. It should also be noted that the mechanism of upregulation of Netrin-4 in the Vc region remains a question and should be explored in the future.

Contrastingly, there was no change in Unc5B mRNA expression in the Vc although it was increased in the spinal cord after nerve injury. This could be attributed to differences between the brain and spinal cord; however, it has been reported that Unc5B mRNA expression decreased and recovered after spinal cord injury [45]. Therefore, Unc5B may show different changes at other time points. Further, it is possible that there are changes in Unc5B protein levels at 14 days after CCI-Sham injury. Therefore, there is a need for further studies. Furthermore, Netrin-4 has been reported to bind to laminin-γ1[46, 47]. Therefore, there is a need to consider the involvement of receptors other than Unc5B.

Moreover, there was no significant difference in mRNA Netrin-4 and Unc5B expression in the Vc between the ipsilateral side and contralateral side despite these differences being observed in the spinal cord. This suggests that SHP2 and NR2B activation change at the ipsilateral side of the Vc similar to in the spinal cord [16]. There is a need for further analysis to elucidate the underlying mechanism.

The analgesic effects of anti-Netrin-4 antibody

We observed that the administration of the anti-Netrin-4 antibody through the cisterna magna increased the head-withdrawal threshold for mechanical stimulation and suppressed neuronal activation in the Vc. These findings suggest that the anti-Netrin-4 antibody presents an analgesic effect by inhibiting the binding of Netrin-4 to Unc5B.

In adult humans, Netrin-4 is present in the heart, kidney, and spleen; further, it is slightly expressed in the brain and spinal cord [7, 48]. The presence of Netrin-4 widely varies in adult healthy brains in rats [14]. There is no abnormality in nerve circuit formation, as well as reproduction and organ formation, in the developmental stage of Netrin-4 knockout rats [16]. The anti-Netrin-4 antibody used in our study has been shown to reduce neuropathic pain caused by infraorbital nerve injury. Moreover, it did not induce significant weight loss or death upon administration. These findings suggest that the anti-Netrin-4 antibody is relative safety in animals and could be applied to humans.

Our findings suggest the following: CCI-ION induced persistent trigeminal nerve excitement and increased Netrin-4 secretion. Subsequently, hyperalgesia was induced by increased Netrin-4 binding to Unc5B. Other than suppressing neuronal activity, anti-Netrin-4 antibody is effective for pain hypersensitivity due to neuropathic pain and could be used in humans in the future.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by Japan Agency for Medical Research and Development (18gm1210005h0001) to T.Y. https://www.amed.go.jp/en/index.html The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain. 152. United States2011. p. 2204–5. 10.1016/j.pain.2011.06.017 [DOI] [PubMed] [Google Scholar]
  • 2.International Association for the Study of P. Diagnosis and classification of neuropathic pain. IASP Pain Clinical Updates. 2010;28:1–6. 10.1016/j.pain.2010.11.027 [DOI] [PubMed] [Google Scholar]
  • 3.Chiba M, Higuchi K, Kondoh T, Echigo S (2008) Clinical picture of neuropathic trigeminal pain provoked by dental treatment. Journal of the Japanese Stomatological Society. 2008;57(4):379–84. . [Google Scholar]
  • 4.Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. The Lancet Neurology. 2010;9(8):807–19. 10.1016/S1474-4422(10)70143-5 [DOI] [PubMed] [Google Scholar]
  • 5.Kennedy TE, Serafini T, de la Torre J, Tessier-Lavigne M. Netrins are diffusible chemotropic factors for commissural axons in the embryonic spinal cord. Cell. 1994;78(3):425–35. 10.1016/0092-8674(94)90421-9 [DOI] [PubMed] [Google Scholar]
  • 6.Cirulli V, Yebra M. Netrins: beyond the brain. Nature reviews Molecular cell biology. 2007;8(4):296. 10.1038/nrm2142 [DOI] [PubMed] [Google Scholar]
  • 7.Koch M, Murrell JR, Hunter DD, Olson PF, Jin W, Keene DR, et al. A Novel Member of the Netrin Family, β-Netrin, Shares Homology with the β Chain of LamininIdentification, Expression, and Functional Characterization. The Journal of cell biology. 2000;151(2):221–34. 10.1083/jcb.151.2.221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Nakashiba T, Ikeda T, Nishimura S, Tashiro K, Honjo T, Culotti JG, et al. Netrin-G1: a novel glycosyl phosphatidylinositol-linked mammalian netrin that is functionally divergent from classical netrins. Journal of Neuroscience. 2000;20(17):6540–50. 10.1523/JNEUROSCI.20-17-06540.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sun KLW, Correia JP, Kennedy TE. Netrins: versatile extracellular cues with diverse functions. Development. 2011;138(11):2153–69. 10.1242/dev.044529 [DOI] [PubMed] [Google Scholar]
  • 10.Schwarting GA, Raitcheva D, Bless EP, Ackerman SL, Tobet S. Netrin 1‐mediated chemoattraction regulates the migratory pathway of LHRH neurons. European Journal of Neuroscience. 2004;19(1):11–20. 10.1111/j.1460-9568.2004.03094.x [DOI] [PubMed] [Google Scholar]
  • 11.Manitt C, Nikolakopoulou AM, Almario DR, Nguyen SA, Cohen-Cory S. Netrin participates in the development of retinotectal synaptic connectivity by modulating axon arborization and synapse formation in the developing brain. Journal of Neuroscience. 2009;29(36):11065–77. 10.1523/JNEUROSCI.0947-09.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Takemoto M, Hattori Y, Zhao H, Sato H, Tamada A, Sasaki S, et al. Laminar and areal expression of unc5d and its role in cortical cell survival. Cerebral cortex. 2011;21(8):1925–34. 10.1093/cercor/bhq265 [DOI] [PubMed] [Google Scholar]
  • 13.Hayano Y, Sasaki K, Ohmura N, Takemoto M, Maeda Y, Yamashita T, et al. Netrin-4 regulates thalamocortical axon branching in an activity-dependent fashion. Proceedings of the National Academy of Sciences. 2014;111(42):15226–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zhang C, Meng F, Wang C, Guo H, Fan M, Liu S, et al. Identification of a novel alternative splicing form of human netrin-4 and analyzing the expression patterns in adult rat brain. Molecular brain research. 2004;130(1–2):68–80. 10.1016/j.molbrainres.2004.07.009 [DOI] [PubMed] [Google Scholar]
  • 15.Manitt C, Thompson KM, Kennedy TE. Developmental shift in expression of netrin receptors in the rat spinal cord: Predominance of UNC‐5 homologues in adulthood. Journal of neuroscience research. 2004;77(5):690–700. 10.1002/jnr.20199 [DOI] [PubMed] [Google Scholar]
  • 16.Hayano Y, Takasu K, Koyama Y, Yamada M, Ogawa K, Minami K, et al. Dorsal horn interneuron-derived Netrin-4 contributes to spinal sensitization in chronic pain via Unc5B. Journal of Experimental Medicine. 2016;213(13):2949–66. 10.1084/jem.20160877 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Vos BP, Strassman AM, Maciewicz RJ. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat’s infraorbital nerve. Journal of Neuroscience. 1994;14(5):2708–23. 10.1523/JNEUROSCI.14-05-02708.1994 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Toyama M, Kudo C, Mukai C, Inoue M, Oyamaguchi A, Hanamoto H, et al. Trigeminal nervous system sensitization by infraorbital nerve injury enhances responses in a migraine model. Cephalalgia. 2017;37(14):1317–28. 10.1177/0333102416678387 [DOI] [PubMed] [Google Scholar]
  • 19.Nakajima A, Tsuboi Y, Suzuki I, Honda K, Shinoda M, Kondo M, et al. PKCγ in Vc and C1/C2 is Involved in Trigeminal neuropathic Pain. Journal of dental research. 2011;90(6):777–81. 10.1177/0022034511401406 [DOI] [PubMed] [Google Scholar]
  • 20.Suzuki I, Tsuboi Y, Shinoda M, Shibuta K, Honda K, Katagiri A, et al. Involvement of ERK phosphorylation of trigeminal spinal subnucleus caudalis neurons in thermal hypersensitivity in rats with infraorbital nerve injury. PLoS One. 2013;8(2). 10.1371/journal.pone.0057278 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Clavelou P, Pajot J, Dallel R, Raboisson P. Application of the formalin test to the study of orofacial pain in the rat. Neuroscience letters. 1989;103(3):349–53. 10.1016/0304-3940(89)90125-0 [DOI] [PubMed] [Google Scholar]
  • 22.Imamura Y, Kawamoto H, Nakanishi O. Characterization of heat-hyperalgesia in an experimental trigeminal neuropathy in rats. Experimental brain research. 1997;116(1):97–103. 10.1007/pl00005748 [DOI] [PubMed] [Google Scholar]
  • 23.Sanuki T, Sakuma Y, Kan Y, Ando T, Kotani J (2007) Formalin Stimulation to Rat Infraorbital Nerve CCI Mode1. Journal of Japanese Dental Society of Anestheology. 2007;35(2):158–62. . [Google Scholar]
  • 24.Scholz J, Woolf CJ. Can we conquer pain? Nature neuroscience. 2002;5(11):1062–7. 10.1038/nn942 [DOI] [PubMed] [Google Scholar]
  • 25.Ji R-R, Woolf CJ. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiology of disease. 2001;8(1):1–10. 10.1006/nbdi.2000.0360 [DOI] [PubMed] [Google Scholar]
  • 26.Ji R-R, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends in neurosciences. 2003;26(12):696–705. 10.1016/j.tins.2003.09.017 [DOI] [PubMed] [Google Scholar]
  • 27.Ji R-R, Gereau Iv RW, Malcangio M, Strichartz GR. MAP kinase and pain. Brain research reviews. 2009;60(1):135–48. 10.1016/j.brainresrev.2008.12.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. science. 2000;288(5472):1765–8. 10.1126/science.288.5472.1765 [DOI] [PubMed] [Google Scholar]
  • 29.Slack SE, Pezet S, McMahon SB, Thompson SWN, Malcangio M. Brain‐derived neurotrophic factor induces NMDA receptor subunit one phosphorylation via ERK and PKC in the rat spinal cord. European Journal of Neuroscience. 2004;20(7):1769–78. 10.1111/j.1460-9568.2004.03656.x [DOI] [PubMed] [Google Scholar]
  • 30.Kohno T, Wang H, Amaya F, Brenner GJ, Cheng J-K, Ji R-R, et al. Bradykinin enhances AMPA and NMDA receptor activity in spinal cord dorsal horn neurons by activating multiple kinases to produce pain hypersensitivity. Journal of Neuroscience. 2008;28(17):4533–40. 10.1523/JNEUROSCI.5349-07.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Zhuang Z-Y, Gerner P, Woolf CJ, Ji R-R. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain. 2005;114(1–2):149–59. 10.1016/j.pain.2004.12.022 [DOI] [PubMed] [Google Scholar]
  • 32.Gao Y-J, Ji R-R. c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury? The open pain journal. 2009;2:11. 10.2174/1876386300902010011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Ji R-R, Baba H, Brenner GJ, Woolf CJ. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nature neuroscience. 1999;2(12):1114–9. 10.1038/16040 [DOI] [PubMed] [Google Scholar]
  • 34.Shibuta K, Suzuki I, Shinoda M, Tsuboi Y, Honda K, Shimizu N, et al. Organization of hyperactive microglial cells in trigeminal spinal subnucleus caudalis and upper cervical spinal cord associated with orofacial neuropathic pain. Brain research. 2012;1451:74–86. 10.1016/j.brainres.2012.02.023 [DOI] [PubMed] [Google Scholar]
  • 35.Wang H, Dai Y, Fukuoka T, Yamanaka H, Obata K, Tokunaga A, et al. Enhancement of stimulation‐induced ERK activation in the spinal dorsal horn and gracile nucleus neurons in rats with peripheral nerve injury. European Journal of Neuroscience. 2004;19(4):884–90. 10.1111/j.0953-816x.2004.03203.x [DOI] [PubMed] [Google Scholar]
  • 36.Gao YJ, Ji RR. Light touch induces ERK activation in superficial dorsal horn neurons after inflammation: involvement of spinal astrocytes and JNK signaling in touch‐evoked central sensitization and mechanical allodynia. Journal of neurochemistry. 2010;115(2):505–14. 10.1111/j.1471-4159.2010.06946.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tong J, Killeen M, Steven R, Binns KL, Culotti J, Pawson T. Netrin stimulates tyrosine phosphorylation of the UNC-5 family of netrin receptors and induces Shp2 binding to the RCM cytodomain. J Biol Chem. 2001;276(44):40917–25. Epub 2001/09/05. 10.1074/jbc.M103872200 . [DOI] [PubMed] [Google Scholar]
  • 38.Krapivinsky G, Krapivinsky L, Manasian Y, Ivanov A, Tyzio R, Pellegrino C, et al. The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron. 2003;40(4):775–84. Epub 2003/11/19. 10.1016/s0896-6273(03)00645-7 . [DOI] [PubMed] [Google Scholar]
  • 39.Kim MJ, Dunah AW, Wang YT, Sheng M. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron. 2005;46(5):745–60. Epub 2005/06/01. 10.1016/j.neuron.2005.04.031 . [DOI] [PubMed] [Google Scholar]
  • 40.Easton JB, Royer AR, Middlemas DS. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor. J Neurochem. 2006;97(3):834–45. Epub 2006/04/01. 10.1111/j.1471-4159.2006.03789.x . [DOI] [PubMed] [Google Scholar]
  • 41.Round J, Stein E. Netrin signaling leading to directed growth cone steering. Curr Opin Neurobiol. 2007;17(1):15–21. Epub 2007/01/27. 10.1016/j.conb.2007.01.003 . [DOI] [PubMed] [Google Scholar]
  • 42.Peng HY, Chen GD, Lai CY, Hsieh MC, Lin TB. Spinal SIRPα1-SHP2 interaction regulates spinal nerve ligation-induced neuropathic pain via PSD-95-dependent NR2B activation in rats. Pain. 2012;153(5):1042–53. Epub 2012/03/20. 10.1016/j.pain.2012.02.006 . [DOI] [PubMed] [Google Scholar]
  • 43.Abbasi M, Gupta V, Chitranshi N, You Y, Dheer Y, Mirzaei M, et al. Regulation of Brain-Derived Neurotrophic Factor and Growth Factor Signaling Pathways by Tyrosine Phosphatase Shp2 in the Retina: A Brief Review. Front Cell Neurosci. 2018;12:85. Epub 2018/04/11. 10.3389/fncel.2018.00085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Lejmi E, Leconte L, Pédron-Mazoyer S, Ropert S, Raoul W, Lavalette S, et al. Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B. Proceedings of the National Academy of Sciences. 2008;105(34):12491–6. 10.1073/pnas.0804008105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ahn KJ, Seo IA, Lee HK, Choi EJ, Seo EH, Lee HJ, et al. Down-regulation of UNC5 homologue expression after the spinal cord injury in the adult rat. Neuroscience letters. 2007;419(1):43–8. 10.1016/j.neulet.2007.03.068 [DOI] [PubMed] [Google Scholar]
  • 46.Schneiders FI, Maertens B, Böse K, Li Y, Brunken WJ, Paulsson M, et al. Binding of netrin-4 to laminin short arms regulates basement membrane assembly. Journal of Biological Chemistry. 2007;282(33):23750–8. 10.1074/jbc.M703137200 [DOI] [PubMed] [Google Scholar]
  • 47.Reuten R, Patel TR, McDougall M, Rama N, Nikodemus D, Gibert B, et al. Structural decoding of netrin-4 reveals a regulatory function towards mature basement membranes. Nature communications. 2016;7(1):1–17. 10.1038/ncomms13515 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Yin Y, Sanes JR, Miner JH. Identification and expression of mouse netrin-4. Mechanisms of development. 2000;96(1):115–9. 10.1016/s0925-4773(00)00369-5 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Masabumi Minami

6 Oct 2020

PONE-D-20-28596

Increased expression of Netrin-4 is associated with allodynia in a trigeminal neuropathic pain model rats by infraorbital nerve injury

PLOS ONE

Dear Dr. Yamashita,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Your manuscript has been assessed by the reviewers. Although it is of interest, we are unable to consider it for publication in its current form. The reviewers have raised several points which we believe would improve the manuscript. 

==============================

Please submit your revised manuscript by Nov 20 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Masabumi Minami, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1) Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2) Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Honjo et al. report the contribution of Netrin-4 to mechanical hypersensitivity in a rat model of trigeminal neuropathic pain. This study is interesting, but I have a few issues that should be addressed.

Major comments

1. The role of Netrin-4 was investigated using its antibody. The authors previously demonstrated its role in neuropathic pain using Netrin-4-mutant rats. Why do they use the mutant rats in this study? If Netrin-4-mutant rats exhibit reduction of behavioral hypersensitivity after infraorbital nerve injury, the authors’ conclusion of this study would be strengthened.

2. Phosphorylated-ERK has been reported to be seen primarily in glial cells (not neurons) 14 days after nerve injury (PMID: 15733640). These cells are crucial for neuronal sensitization associated with neuropathic pain (PMID: 19741123). Did the authors detect p-ERK in astrocytes or microglia in the Vc after nerve injury?

3. Netrin-4 expression is also increased in the contralateral side at day 14 (Figure 4). However, pain threshold in the contralateral side at that time was normal (Figure 1). These data imply that Netrin-4 is not sufficient to mechanical hypersensitivity. On the other hand, the authors previously reported that intrathecal administration of Netrin-4 to normal rats induces mechanical hypersensitivity. How do the authors reconcile the discrepancy? This should be discussed.

Minor comment

1. (Line 258-260) The authors might mistakenly cite Refs #30 and 31 (these papers do not use a spinal cord injury model).

Reviewer #2: The authors of this work have shown that the expression of Netrin-4 is increased in the Vc 14 days after ligation of infraorbital nerve, and thereby activation of Netrin-4/Unc5B signaling axis are responsible for the development of neuropathic pain after ION-CCI. Each result may not be novel, but the hypotheses of this study have been theoretically tested and discussed, and the manuscript is well-written. However, in the current format, the clarity of these findings should not be enough. There are several points that the authors should further address to their excellent manuscript.

Major Comment

1. Throughout the manuscript, there seems to be a lack of explanation of the Netrin-4/Unc5B signaling axis in the Vc region that are activated after ION-CCI. For example, it is unclear how Netrin-4 is up-regulated in the VC region after nerve injury. It is also difficult to understand how the authors conclude that Netrin-4 is upregulated in interneurons IN THE VC region. Furthermore, it would also be necessary to mention through what signaling pathway ERK is activated after Netrin-4 binds to Unc5B.

2. The authors argued that Netrin-4 may participate in the sensitization process leading to neuropathic pain. Of course, their study using anti-Netrin-4 antibody highlight pro-nociceptive roles of Netrin-4. However, based on the series of there findings, it is not sufficient to conclude that netrin-4 is involved in central sensitization. For example, their conclusions would be reinforced by showing the time course of changes in netrin-4 expression after ION-CCI.

3. In order to conclude the nociceptive roles of Netrin-4 in the Vc, I strongly recommend not only to experiment with neutralizing Netrin-4 antibody, but also to investigate whether the administration of recombinant Netrin-4 protein mimics pain behaviors and activation of ERK in the Vc.

4. My major concern with their data is that complete lack of staining images in the figures. For example, in figure 3, immunohistochemical images of contralateral side and images in the netrin-4 neutralizing antibody treatment group are absolutely necessary. Similarly, staining images of contralateral and ipsilateral side on day 0 and 14 MUST be included in figure 4.

5. Although the authors have proposed a role for netrin-4 in the development of pain, netrin-4-positive cells appear to be a few in the Vc even after ION-CCI. This discrepancy needs to be explained in the manuscript.

Minor Comment

1. P.11, line 215: Is the sentence "we performed quantitative mRNA analysis by RT-PCR." correct? I think they conducted qPCR analysis in the study, and should be corrected.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Apr 29;16(4):e0251013. doi: 10.1371/journal.pone.0251013.r002

Author response to Decision Letter 0


25 Mar 2021

Reviewer #1:

Major comments

1. The role of Netrin-4 was investigated using its antibody. The authors previously demonstrated its role in neuropathic pain using Netrin-4-mutant rats. Why do they use the mutant rats in this study? If Netrin-4-mutant rats exhibit reduction of behavioral hypersensitivity after infraorbital nerve injury, the authors’ conclusion of this study would be strengthened.

Netrin-4 mutant rats show developmental abnormality of the thalamocortical axon branching (ref. 13 in the manuscript). Therefore, if hyperalgesia does not occur in the maxillofacial region after CCI-ION in the mutant rats, we should consider the possibility that the abnormal wiring of the sensory neural pathway may cause this effect. In addition, some previous reports (References [1-3] in this letter) show that Netrin-4 mutant animals show abnormal vascular structure in retina and in blood vessels in the trigeminal nerve area. In the present study, we intended to assess if transient suppression of Netrin-4 was effective in suppressing hypersensitivity after infraorbital nerve injury. Practically, Netrin-4-mutant rats are not currently available due to reconstruction of the animal testing facility in Osaka University. Therefore, we decided not to perform the experiments using Netrin-4 mutant rats.

2. Phosphorylated-ERK has been reported to be seen primarily in glial cells (not neurons) 14 days after nerve injury (PMID: 15733640). These cells are crucial for neuronal sensitization associated with neuropathic pain (PMID: 19741123). Did the authors detect p-ERK in astrocytes or microglia in the Vc after nerve injury?

We added images that show immunohistochemical staining for pERK in astrocytes and microglia (Figure 3C, D). However, we could not detect pERK signals in astrocyte or microglia (page 10, last paragraph).

3. Netrin-4 expression is also increased in the contralateral side at day 14 (Figure 4). However, pain threshold in the contralateral side at that time was normal (Figure 1). These data imply that Netrin-4 is not sufficient to mechanical hypersensitivity. On the other hand, the authors previously reported that intrathecal administration of Netrin-4 to normal rats induces mechanical hypersensitivity. How do the authors reconcile the discrepancy? This should be discussed.

We carried out additional experiments to address the point raised by the reviewer. We examined expression of Netrin-4 and Unc5B at days 0 and 14 (Figure 5A, B, E, F), and after anti-Netrin-4 antibody or control antibody treatment (Figure 5C, D, G, H). We did not observe the difference of the expression of Netrin-4 between ipsilateral and contralateral side in each group examined (Figure 5A-H).

Then, we tried administration of Netrin-4 from cisterna magna of rats, but could not observe mechanical hypersensitivity in the area of infraorbital nerve (data not shown). From these observations, we considered that Netrin-4 may enhance hypersensitivity following damage to the infraorbital nerve, but that Netrin-4 is not sufficient to induce hypersensitivity.

We stated in the text as follow (page 14, last paragraph ~ page 15, first paragraph). “We observed that anti-Netrin-4 antibody administration through the cisterna magna increased the escape threshold by CCI-ION and reduced neuronal pERK expression in the Vc. However, Netrin-4 expression is increased also in the contralateral side at day 14. These findings suggest that Netrin-4 enhances hypersensitivity induced by damage to the infraorbital nerve, but that Netrin-4 is not sufficient to induce hypersensitivity. The molecular mechanism of the effect of Netrin-4 in the Vc might be explained by the previous observations that Netrin-4 binding to Unc5B leads to activation of SHP2 and the Ras-MAPK pathway [16, 37-43] .”

Minor comment

1. (Line 258-260) The authors might mistakenly cite Refs #30 and 31 (these papers do not use a spinal cord injury model).

We corrected those references.

Reviewer #2:

Major Comment

1. Throughout the manuscript, there seems to be a lack of explanation of the Netrin-4/Unc5B signaling axis in the Vc region that are activated after ION-CCI. For example, it is unclear how Netrin-4 is up-regulated in the VC region after nerve injury. It is also difficult to understand how the authors conclude that Netrin-4 is upregulated in interneurons in the VC region. Furthermore, it would also be necessary to mention through what signaling pathway ERK is activated after Netrin-4 binds to Unc5B.

The mechanism of upregulation of Netrin-4 in the Vc region remains a question. We added the description (page 15, third paragraph).

Regarding the cell types, we could not conclude that Netrin-4 was upregulated in interneurons in the VC region. Therefore, we did not mention that Netrin-4 was upregulated in interneurons in the VC region. In the CCI model, we identified that the central cells in the spinal cord were the source of Netrin-4 (ref 16 in the manuscript). However, the current knowledge about the interneurons in the Vc is sparce and we could not determine the exact cell type that expressed Netrin-4 in the present study.

Regarding the signaling pathway, we added discussion (page 14, last paragraph ~ page 15, first paragraph). “We observed that anti-Netrin-4 antibody administration through the cisterna magna increased the escape threshold by CCI-ION and reduced neuronal pERK expression in the Vc. However, Netrin-4 expression is increased also in the contralateral side at day 14. These findings suggest that Netrin-4 enhances hypersensitivity induced by damage to the infraorbital nerve, but that Netrin-4 is not sufficient to induce hypersensitivity. The molecular mechanism of the effect of Netrin-4 in the Vc might be explained by the previous observations that Netrin-4 binding to Unc5B leads to activation of SHP2 and the Ras-MAPK pathway [16, 37-43] .”

2. The authors argued that Netrin-4 may participate in the sensitization process leading to neuropathic pain. Of course, their study using anti-Netrin-4 antibody highlight pro-nociceptive roles of Netrin-4. However, based on the series of there findings, it is not sufficient to conclude that netrin-4 is involved in central sensitization. For example, their conclusions would be reinforced by showing the time course of changes in netrin-4 expression after ION-CCI.

We analyzed the time course changes of netrin-4 and Unc5B expression after ION-CCI by real-time PCR. Compared with pre-injury levels, there was a significant increase in the Netrin-4, but not Unc5b, levels from 7 to 21 days after CCI-Sham injury (Figure 4G, H).

3. In order to conclude the nociceptive roles of Netrin-4 in the Vc, I strongly recommend not only to experiment with neutralizing Netrin-4 antibody, but also to investigate whether the administration of recombinant Netrin-4 protein mimics pain behaviors and activation of ERK in the Vc.

We previously reported that intrathecal administration of Netrin-4 to normal rats’ spinal cord induced mechanical hypersensitivity (ref 16 in the manuscript). In order to address the point raised by the reviewer, we tried administration of Netrin-4 from cisterna magna of rats, but could not observe mechanical hypersensitivity in the area of infraorbital nerve (data not shown). From these data, we considered that Netrin-4 may enhance hypersensitivity following damage to the infraorbital nerve, but that Netrin-4 is not sufficient to induce hypersensitivity (page 14, last paragraph ~ page 15, first paragraph).

4. My major concern with their data is that complete lack of staining images in the figures. For example, in figure 3, immunohistochemical images of contralateral side and images in the netrin-4 neutralizing antibody treatment group are absolutely necessary. Similarly, staining images of contralateral and ipsilateral side on day 0 and 14 MUST be included in figure 4.

We examined expression of Netrin-4 and Unc5B at days 0 and 14 (Figure 5A, B, E, F), and after anti-Netrin-4 antibody or control antibody treatment (Figure 5C, D, G, H). We did not observe the difference of the expression of Netrin-4 between ipsilateral and contralateral side in each group examined (Figure 5A-H). Moreover, we added the images for pERK staining with or without anti-Netrin-4 antibody treatment (Figure 3F)

5. Although the authors have proposed a role for netrin-4 in the development of pain, netrin-4-positive cells appear to be a few in the Vc even after ION-CCI. This discrepancy needs to be explained in the manuscript.

In our study, although the number of Netrin-4-positive cells in the Vc appear to be a few, it may reflect the sensitivity of the antibodies employed. As Netrin-4 is a secreted protein, it would be difficult to detect the low amount of the Netrin-4 protein by immunohistochemistry. We added the description in Discussion (page 15, second paragraph).

Minor Comment

1. P.11, line 215: Is the sentence "we performed quantitative mRNA analysis by RT-PCR." correct? I think they conducted qPCR analysis in the study, and should be corrected.

We corrected the text. (P.11, first paragraph “we performed quantitative mRNA analysis by RT-PCR.”→ “we performed quantitative mRNA analysis by real-time PCR.”)

1. Crespo-Garcia S, Reichhart N, Wigdahl J, Skosyrski S, Kociok N, Strauß O, et al. Lack of netrin-4 alters vascular remodeling in the retina. Graefes Arch Clin Exp Ophthalmol. 2019;257(10):2179-84. Epub 2019/08/28. doi: 10.1007/s00417-019-04447-3. PubMed PMID: 31451908.

2. Crespo-Garcia S, Reichhart N, Wigdahl J, Skosyrski S, Kociok N, Strauß O, et al. Correction to: Lack of netrin-4 alters vascular remodeling in the retina. Graefes Arch Clin Exp Ophthalmol. 258. Germany2020. p. 217.

3. Kociok N, Crespo-Garcia S, Liang Y, Klein SV, Nürnberg C, Reichhart N, et al. Lack of netrin-4 modulates pathologic neovascularization in the eye. Sci Rep. 2016;6:18828. Epub 2016/01/07. doi: 10.1038/srep18828. PubMed PMID: 26732856; PubMed Central PMCID: PMCPMC4702134.

4. Hayano Y, Takasu K, Koyama Y, Yamada M, Ogawa K, Minami K, et al. Dorsal horn interneuron-derived Netrin-4 contributes to spinal sensitization in chronic pain via Unc5B. Journal of Experimental Medicine. 2016;213(13):2949-66.

5. Tong J, Killeen M, Steven R, Binns KL, Culotti J, Pawson T. Netrin stimulates tyrosine phosphorylation of the UNC-5 family of netrin receptors and induces Shp2 binding to the RCM cytodomain. J Biol Chem. 2001;276(44):40917-25. Epub 2001/09/05. doi: 10.1074/jbc.M103872200. PubMed PMID: 11533026.

6. Krapivinsky G, Krapivinsky L, Manasian Y, Ivanov A, Tyzio R, Pellegrino C, et al. The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron. 2003;40(4):775-84. Epub 2003/11/19. doi: 10.1016/s0896-6273(03)00645-7. PubMed PMID: 14622581.

7. Kim MJ, Dunah AW, Wang YT, Sheng M. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron. 2005;46(5):745-60. Epub 2005/06/01. doi: 10.1016/j.neuron.2005.04.031. PubMed PMID: 15924861.

8. Easton JB, Royer AR, Middlemas DS. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor. J Neurochem. 2006;97(3):834-45. Epub 2006/04/01. doi: 10.1111/j.1471-4159.2006.03789.x. PubMed PMID: 16573649.

9. Round J, Stein E. Netrin signaling leading to directed growth cone steering. Curr Opin Neurobiol. 2007;17(1):15-21. Epub 2007/01/27. doi: 10.1016/j.conb.2007.01.003. PubMed PMID: 17254765.

10. Peng HY, Chen GD, Lai CY, Hsieh MC, Lin TB. Spinal SIRPα1-SHP2 interaction regulates spinal nerve ligation-induced neuropathic pain via PSD-95-dependent NR2B activation in rats. Pain. 2012;153(5):1042-53. Epub 2012/03/20. doi: 10.1016/j.pain.2012.02.006. PubMed PMID: 22425446.

11. Abbasi M, Gupta V, Chitranshi N, You Y, Dheer Y, Mirzaei M, et al. Regulation of Brain-Derived Neurotrophic Factor and Growth Factor Signaling Pathways by Tyrosine Phosphatase Shp2 in the Retina: A Brief Review. Front Cell Neurosci. 2018;12:85. Epub 2018/04/11. doi: 10.3389/fncel.2018.00085. PubMed PMID: 29636665; PubMed Central PMCID: PMCPMC5880906.

Attachment

Submitted filename: Honjo_rebuttal.docx

Decision Letter 1

Masabumi Minami

19 Apr 2021

Increased expression of Netrin-4 is associated with allodynia in a trigeminal neuropathic pain model rats by infraorbital nerve injury

PONE-D-20-28596R1

Dear Dr. Yamashita,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Masabumi Minami, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The authors have responded to the questions posed in the previous manuscript with appropriate answers and additional experiments, and I feel the manuscript has been greatly improved. I have no further questions.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Acceptance letter

Masabumi Minami

21 Apr 2021

PONE-D-20-28596R1

Increased expression of Netrin-4 is associated with allodynia in a trigeminal neuropathic pain model rats by infraorbital nerve injury

Dear Dr. Yamashita:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Masabumi Minami

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Honjo_rebuttal.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES